Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Core Insights - Alvotech announced positive top-line results from a pharmacokinetic study for AVT80, a biosimilar candidate to Entyvio, meeting all primary endpoints [1][2][3] Study Details - The pharmacokinetic study (AVT80-GL-P01) was a randomized, double-blind, single-dose, parallel-group design involving healthy adult participants, aimed at demonstrating PK similarity and assessing safety, tolerability, and immunogenicity profiles of AVT80 compared to Entyvio after a single 108 mg subcutaneous injection [2][4] - The study results support the demonstration of clinical similarity for both AVT80 and AVT16, another proposed biosimilar to Entyvio for intravenous administration [4] Market Context - Entyvio (vedolizumab) is used for treating moderate to severe Ulcerative Colitis and Crohn's disease, with combined net revenues of approximately US$6.4 billion in 2025 [5] - Alvotech aims to be a global leader in the biosimilar market, focusing on high-quality, cost-effective products, with a pipeline that includes nine disclosed biosimilar candidates targeting various diseases [8] Company Overview - Alvotech specializes in the development and manufacture of biosimilar medicines, with two biosimilars already approved and marketed globally [8] - The company has established strategic commercial partnerships to enhance its market reach across the United States, Europe, Japan, China, and other regions [8]